Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Scioderm Inc.
Our chart details the pipeline candidates who might lose the coveted status as treatment paradigms change and trial results come in.
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
FDA started off 2016 with a spate of new breakthrough therapy designations, feeding the popular program – and fueling agency concerns about workforce strain.
Day-by-day updates from the J.P. Morgan Healthcare Conference Jan. 11-14 in San Francisco.